Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 957 participants.

Also called NCT05359068

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 957 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05359068
Other papers using this trial's data
  • Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial Drugs, 2026-07 DOI, PubMed 42165988, PMC13290787 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05359068. Randomized; double masking; primary purpose treatment. Start 2021-06-10 (actual); primary completion 2023-12-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
SPH3127 tablet
Intervention (Drug)
SPH3127 tablet
Intervention (Drug)
SPH3127 tablet
Intervention (Drug)
Valsartan
Intervention (Drug)
SPH3127 tablet
Intervention (Drug)
Valsartan
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct05359068
Content hash
291e3c74cd6528de31c97f01156edbf4d646b5586ee05e6ba8568ec73848121f